Compare · AMGN vs TAK
AMGN vs TAK
Side-by-side comparison of Amgen Inc. (AMGN) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AMGN focuses on Biotechnology: Biological Products (No Diagnostic Substances), while TAK focuses on Biotechnology: Pharmaceutical Preparations.
- AMGN is the larger of the two at $177.88B, about 3.4x TAK ($52.09B).
- Over the past year, AMGN is up 21.9% and TAK is up 8.9% - AMGN leads by 13.0 points.
- AMGN has been more active in the news (21 items in the past 4 weeks vs 12 for TAK).
- AMGN has more recent analyst coverage (25 ratings vs 6 for TAK).
- Company
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Price
- $329.55+1.78%
- $16.53-0.18%
- Market cap
- $177.88B
- $52.09B
- 1M return
- -3.80%
- -9.33%
- 1Y return
- +21.89%
- +8.89%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1983
- 2018
- News (4w)
- 21
- 12
- Recent ratings
- 25
- 6
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest AMGN
- EVP, Operations Santos Esteban covered exercise/tax liability with 1,338 shares, decreasing direct ownership by 2% to 81,066 units (SEC Form 4)
- EVP & Chief Technology Officer Reese David M covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 3% to 40,354 units (SEC Form 4)
- SVP, Human Resources Miller Derek covered exercise/tax liability with 365 shares, decreasing direct ownership by 3% to 11,808 units (SEC Form 4)
- SVP, Business Development Khosla Rachna covered exercise/tax liability with 225 shares, decreasing direct ownership by 3% to 8,066 units (SEC Form 4)
- SVP & CCO Grygiel Nancy A. covered exercise/tax liability with 242 shares and sold $400,451 worth of shares (1,237 units at $323.73), decreasing direct ownership by 17% to 7,009 units (SEC Form 4)
- EVP & CFO Griffith Peter H. covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 3% to 47,568 units (SEC Form 4)
- EVP & Gen. Counsel & Sec. Graham Jonathan P covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 3% to 38,010 units (SEC Form 4)
- EVP, Global Commercial Ops Gordon Murdo covered exercise/tax liability with 1,593 shares, decreasing direct ownership by 3% to 48,699 units (SEC Form 4)
- VP, Finance & CAO Busch Matthew C. covered exercise/tax liability with 68 shares, decreasing direct ownership by 2% to 3,980 units (SEC Form 4)
- Chairman, CEO and President Bradway Robert A covered exercise/tax liability with 5,057 shares, decreasing direct ownership by 1% to 496,805 units (SEC Form 4)
Latest TAK
- British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome
- SEC Form 3 filed by new insider Smoter Jennifer Marie
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- President and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes
- President, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)
- Head, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,740 units of American Depositary Shares, increasing direct ownership by 19% to 172,348 units (SEC Form 4)
- Chief Transformation Officer Duprey Lauren Rusckowski was granted 59,990 units of American Depositary Shares, increasing direct ownership by 36% to 228,503 units (SEC Form 4)
- CEO - Elect Kim Julie So-Young was granted 105,416 units of American Depositary Shares, increasing direct ownership by 32% to 430,145 units (SEC Form 4)
- Chief Data & Tech. Officer Ricci Gabriele was granted 34,994 units of American Depositary Shares, increasing direct ownership by 28% to 159,126 units (SEC Form 4)
- Chief Financial Officer Furuta Milano was granted 7,800 units of Ordinary Shares, increasing direct ownership by 16% to 57,900 units (SEC Form 4) (withholding obligation)